Search Results

The KRONUS Zinc Transporter 8 Autoantibody (ZnT8Ab) ELISA Assay is for the semi-quantitative determination of autoantibodies to Zinc Transporter 8 (ZnT8) in human serum. The KRONUS Zinc Transporter 8 Autoantibody (ZnT8Ab) ELISA Assay may be useful as an aid in the diagnosis of Type 1 diabetes mellitus (autoimmune mediated diabetes). The ZnT8Ab assay is not to be used alone and is to be used in conjunction with other clinical and laboratory findings.

The KRONUS Zinc Transporter 8 Autoantibody (ZnT8Ab) ELISA Assay contains the following: strip wells coated with ZnT8 (96 wells in total) and supplied as 12 strips of 8 wells in a frame and sealed in a foil bag with desiccant; ready-to-use 4 levels of calibrators (10, 20, 75, and 500 U/mL, 5x0.7 mL each); one each ready-to-use positive I, positive II and negative control serum (1x0.7 mL); Zinc T8 Biotin (lyophilized) 3x5.5 mL (reconstituted); ready-to-use reconstitution buffer for Zinc T8 Biotin 2x15 mL (colored red); Streptavidin Peroxidase (SA-POD dilute before use) 1x0.7 mL; ready-to-use diluent for SA-POD 1x15 mL; ready-to-use peroxidase substrate (TMB) 1x15 mL; concentrated wash solution (dilute with deionized water before use) 1x125 mL and ready-to-use stop solution 1x12 mL.

Here's a summary of the acceptance criteria and the study that proves the device meets them, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance:

The document doesn't explicitly state "acceptance criteria" as a separate, pre-defined set of thresholds that the device must meet. Instead, it describes performance characteristics that were evaluated and determined to be acceptable for classification. The "clinical validation results must demonstrate clinical sensitivity and clinical specificity for the test values based on the presence or absence of Type 1 diabetes mellitus." The benefits and risks section effectively summarizes what was found and deemed acceptable.

Therefore, the table below reflects the presented clinical performance data which, given the overall conclusion, can be interpreted as the device meeting the implied acceptance criteria.

2. Sample Size Used for the Test Set and Data Provenance:

• Test Set Sample Size: 569 clinically defined patient samples.
  • 323 patients with Type 1 diabetes mellitus (T1D).
  • 246 patients from non-target disease groups (60 Type 2 diabetes mellitus, and 186 other autoimmune/medical conditions).
• Data Provenance: Not explicitly stated regarding country of origin. The study appears to be retrospective, as the patients were "clinically defined" with existing diagnoses.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications:

The document does not specify the number of experts or their qualifications for establishing the ground truth for the clinical sample diagnoses. It simply states that the "diagnosis of Type 1 diabetes mellitus must be based on clinical history, physical examination, and laboratory tests, such as one or more pancreatic or insulin autoantibody test." Similarly, "Diseases for the differential groups must be based on established diagnostic criteria and clinical evaluation."

4. Adjudication Method for the Test Set:

The document does not describe an adjudication method for establishing the ground truth diagnoses for the clinical test set. It refers to diagnoses being "clinically defined" or based on "established diagnostic criteria and clinical evaluation."

5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study Was Done:

No, an MRMC comparative effectiveness study was not done. This study assesses the standalone performance of the KRONUS Zinc Transporter 8 Autoantibody ELISA Assay. The device is intended to be used "in conjunction with other clinical and laboratory findings," but its performance is evaluated in isolation against clinical diagnoses.

6. If a Standalone Performance Study Was Done:

Yes, a standalone study was done. The performance characteristics (sensitivity, specificity) presented for the KRONUS ZnT8Ab ELISA Assay are based on the device's output alone compared to the clinical diagnoses of the 569 patient samples.

7. The Type of Ground Truth Used (Expert Consensus, Pathology, Outcomes Data, etc.):

The ground truth for the test set was clinical diagnosis, based on:

• "clinical history, physical examination, and laboratory tests, such as one or more pancreatic or insulin autoantibody test" for Type 1 diabetes mellitus.
• "established diagnostic criteria and clinical evaluation" for the differential diagnosis groups.

This can be categorized as a form of clinical diagnosis/expert assessment, although the involvement of specific "experts" is not detailed.

8. The Sample Size for the Training Set:

The document does not explicitly mention a separate "training set" for the development of the assay's core diagnostic algorithm (e.g., how the assay generates its U/mL values). The closest approximation to a "training" or "development" process is the determination of the assay cut-off.

• Assay Cut-off Determination: The cut-off of 15 U/mL was determined by testing 397 US healthy blood donors. This can be considered the dataset used to establish the "normal" range and thus define the threshold for a positive result.

9. How the Ground Truth for the Training Set Was Established:

For the assay cut-off determination:

• Ground Truth: The 397 individuals were identified as "healthy blood donors." This implies their healthy status was the ground truth against which the assay results were compared to set the cut-off.
• Method: 99% (394/397) of these healthy individuals were negative for ZnT8Ab. The mean and SD of results from these donors were used to establish the cut-off, with the goal of identifying 99th percentile or similar for negatives.

Ask a specific question about this device